Company / Cash & Equivalents
ARDELYX, INC. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$68.0M
FY2025
5-year range
$21.5M / $96.1M
FY2021-FY2025
Trend
+4.7%
vs FY2024
Sector context
#168 of 207
Health Care
What the data says
ARDELYX, INC.'s cash & equivalents of $68M is lower than 81% of companies in the Health Care sector (FY2025). Cash & Equivalents has fluctuated over the past 10 years, ranging from $21M in FY2023 to $181M in FY2019.
Based on SEC 10-K filings.
$68M in FY2025 with a 5-year CAGR of -5.7%.
Improved from $21M to $68M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -10.9%
- 5-Year CAGR
- -5.7%
- 10-Year CAGR
- -
Sector benchmark
Bottom 19% in Health CareTop 81% of 207This company $68.0M Sector average $669.5M
▼
-89.8% below sector average
Key checks
Key Insights
- 5-year CAGR of -5.7%, indicating a declining trend.
- In FY2025, cash & equivalents increased 4.7% year-over-year.
- Ranks #168 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.41 (distress zone, below 1.8 threshold)
- Negative profit margin: -11.7%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $68.0M | +4.7% |
| FY2024 | $64.9M | +202.4% |
| FY2023 | $21.5M | -77.7% |
| FY2022 | $96.1M | +32.7% |
| FY2021 | $72.4M | -20.4% |
| FY2020 | $91.0M | -49.7% |
| FY2019 | $181.1M | +130.0% |
| FY2018 | $78.8M | -26.4% |
| FY2017 | $107.0M | -0.3% |
| FY2016 | $107.3M | +0.3% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026